Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases

• 作者: Anil Kapoor Himu Lukka Ian Dayes Nathan C Wong Sebastien Hotte Som Mukherjee Yuding Wang
• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2020,（4）
• 页码范围: 437-438
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/aja.aja_66_19

摘要

Dear Editor, Approximately 90％ of men with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases that can cause excruciating pain,bone fractures,disability,and death.1-3 Radium-223 is a radioactive isotope that mimics calcium and emits alpha particle radiation that selectively targets bone metastases.4,5 The results from the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study,a phase 3 randomized controlled trial,showed that radium-223 improved overall survival (OS) and time to symptomatic skeletalrelated events (SRE) in men with mCRPC and bone metastases compared to placebo6 Despite the FDA approval,radium-223 appears to be less utilized for the treatment of mCRPC compared to oral agents that target the androgen receptor pathway.We report our initial experience and outcomes of men with mCRPC and bone metastases treated with radium-223.